Results 21 to 30 of about 3,943 (171)
Research in Pharmaceutical Sciences, 2022 Background and purpose: The lack of a new effective treatment for small cell lung cancer (SCLC) is an unresolved problem. Due to the new identification of delta-like ligand 3 (DLL3) and its high expression in SCLC patients, the use of DLL3 in target ...
Mohammad Hossein Ataee +5 more
doaj +1 more source
Immunotoxins Immunotherapy against Hepatocellular Carcinoma: A Promising Prospect
Toxins, 2021 Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. Therefore, fighting against such cancer is reasonable. Chemotherapy drugs are sometimes inefficient and often accompanied by undesirable side effects for patients.
Mohammad Heiat +3 more
doaj +1 more source
Recombinant immunotoxins development for HER2-based targeted cancer therapies
Cancer Cell International, 2021 Understanding the molecular mechanisms of cancer biology introduces targeted therapy as a complementary method along with other conventional therapies. Recombinant immunotoxins are tumor specific antibodies that their recognizing fragment is utilized for
Reza Mahmoudi +6 more
doaj +1 more source
Immunotoxins: Targeted Toxin Delivery for Cancer Therapy
Pharmaceutical Fronts, 2019 Immunotoxins are proteins that consist of a protein toxin conjugated to a specific targeting moiety. The targeting moiety is usually an antibody or ligand, such as monoclonal antibody, antibody fragment, a cytokine, or a growth factor. The toxins usually
Xin Mei +3 more
doaj +1 more source
Mechanisms of Resistance to Immunotoxins Containing Pseudomonas Exotoxin A in Cancer Therapy
Biomolecules, 2020 Immunotoxins are a class of targeted cancer therapeutics in which a toxin such as Pseudomonas exotoxin A (PE) is linked to an antibody or cytokine to direct the toxin to a target on cancer cells.
Michael Dieffenbach, Ira Pastan
doaj +1 more source
Toxins, 2022 Immunotoxins do not only bind to cancer-specific receptors to mediate the elimination of tumor cells through the innate immune system, but also increase target cytotoxicity by the intrinsic toxin activity.
Hossein Panjideh +3 more
doaj +1 more source
Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update
Biomolecules, 2020 Hepatocellular carcinoma (HCC) accounts for most liver cancers and represents one of the deadliest cancers in the world. Despite the global demand for liver cancer treatments, there remain few options available. The U.S. Food and Drug Administration (FDA)
Bryan D. Fleming, Mitchell Ho
doaj +1 more source
Toxins, 2019 Immunotoxins are protein drugs composed of a targeting domain genetically fused to a protein toxin. One killing domain being explored is a truncated Pseudomonas exotoxin A (PE).
Yasmin Leshem, Ira Pastan
doaj +1 more source
Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A
Toxins, 2016 Recombinant immunotoxins (RITs) are fusions of an Fv-based targeting moiety and a toxin. Pseudomonas exotoxin A (PE) has been used to make several immunotoxins that have been evaluated in clinical trials.
Gilad Kaplan +6 more
doaj +1 more source
Blood, 2014 AbstractUnconjugated monoclonal antibodies that target hematopoietic differentiation antigens have been developed to treat hematologic malignancies. Although some of these have activity against chronic lymphocytic leukemia and hairy cell leukemia, in general, monoclonal antibodies have limited efficacy as single agents in the treatment of leukemia.
Alan S, Wayne +3 more
openaire +3 more sources